Ipca Laboratories launches Diulcus

17 Aug 2024 Evaluate

Ipca Laboratories has launched Diulcus, a novel product aimed at addressing the challenges of Diabetic Foot Ulcer (DFU) in the Indian market. Diulcus, developed by NovaLead Pharma, a pioneer in drug repurposing, represents a significant advancement in the management of DFU. The product has received approval from the Central Drugs Standard Control Organization (CDSCO) and was partially funded by the Biotechnology Industry Research Assistance Council (BIRAC), a Government of India enterprise.

Diulcus will be made available to the patients of DFU by Ipca Laboratories through an exclusive IP licensing arrangement with NovaLead for Indian starting August 2024.

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations.


Ipca Laboratories Share Price

1417.75 -28.40 (-1.96%)
25-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.85
Dr. Reddys Lab 1173.55
Cipla 1525.50
Lupin 2018.35
Zydus Lifesciences 859.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...